NewKerala.com

NIPER Raebareli Teams Up with Lofty Labs for Drug Research

NIPER Raebareli signed a MoU, CDA, and TTA with Lofty Laboratories to boost pharma research and tech commercialisation. The partnership will adopt an industry-ready technology from NIPER for further development. This collaboration aims to reduce the cost of gel-staining agents used in biology research. The initiative marks a step towards strengthening India's pharma and biotech sectors through indigenous innovation.

Key Points: NIPER Raebareli & Lofty Labs MoU for Pharma Innovation

  • NIPER Raebareli signs MoU with Lofty Laboratories
  • Agreement includes technology transfer for industry-ready tech
  • Focus on pharmaceutical and biotechnology research
  • Aims to reduce cost of gel-staining agents for biology research
2 min read

NIPER Raebareli signs MoU with Lofty Laboratories for pharma research, tech commercialisation

NIPER Raebareli signs MoU with Lofty Laboratories for pharma research and tech commercialisation, aiming to boost indigenous innovation.

"commercialisation of the present technology would help reduce the cost of gel-staining agents - Nihar Ranjan"

New Delhi, May 8

The National Institute of Pharmaceutical Education and Research, Raebareli, on Friday signed a Memorandum of Understanding, Confidential Disclosure Agreement, and Technology Transfer Agreement with Lofty Laboratories, Hyderabad, to strengthen collaboration in pharmaceutical research, innovation and technology commercialisation.

According to the Ministry of Chemicals and Fertilisers, the agreement aims to foster multidirectional collaboration between academia and industry in pharmaceutical and biotechnology research.

As part of the collaboration, both organisations agreed to adopt an industry-ready technology developed at NIPER-Raebareli for further development and commercialisation. The partnership will also include joint research and development activities in areas of mutual interest.

Speaking on the occasion, NIPER-Raebareli Director Shubhini A. Saraf, said the MoU and technology transfer agreement would help both institutions complement each other's research programmes through collaborative participation in the Institute's Centre of Excellence on Novel Drug Delivery System (CoE-NDDS).

Saraf also highlighted the significance of technologies being developed at the Centre of Excellence and expressed hope that several more technologies from the institute would be ready for transfer by the end of the year.

Head of CoE-NDDS, Nihar Ranjan, said commercialisation of the present technology would help reduce the cost of gel-staining agents that are widely used in biology-related research, including studies involving genes, cancer and other nucleic acid-related diseases.

He added that indigenous production of such novel gel-staining agents would contribute substantially towards strengthening India's pharmaceutical and biotechnology sectors.

According to the ministry, the collaboration marks a significant step towards advancing academia-industry partnerships and promoting indigenous innovation in the pharmaceutical and biotechnology sectors.

- ANI

Share this article:

Reader Comments

P
Priya S
Good to see NIPER institutions actively pursuing industry tie-ups. However, I hope this isn't just a one-off MoU signing ceremony. Many such agreements in the past have fizzled out without real outcomes. Would love to see concrete timelines and deliverables for the technology transfer and commercialisation mentioned here.
V
Vikram M
Fantastic news for Indian pharma R&D! 🇮🇳 The focus on indigenous production of gel-staining agents is particularly important - we've been dependent on foreign suppliers for too long. If NIPER-Raebareli can deliver multiple technologies by year-end as mentioned, it will be a game-changer for our self-reliance in biotech tools.
A
Ananya R
As a biology researcher, this is heartening! Gel-staining agents are a significant recurring cost in our labs. If this technology leads to affordable, India-made alternatives, it will save crores in research expenditure annually. Hope Lofty Laboratories moves quickly with commercialisation and keeps pricing reasonable for academic institutions.
J
James A
Interesting development. Academic-industry collaborations are common in Western countries but still underutilized in India. The key will be whether this partnership focuses on genuine innovation versus just replicating existing technologies. The mention of gel-staining agents for nucleic acid research sounds promising though.
R
Rohit P
Finally, some meaningful progress in pharma research! 😊 But I'm a bit skeptical about how many technologies will actually be "ready for transfer" by year-end. In my experience, these timelines often get extended. Still, it's a step in the right direction - let's hope it's not just another press release with no real action.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50